Cover Image
Market Research Report
Product code
981989

LAMEA Autoinjectors Market By Type, By Application, By End Use, By Country, Industry Analysis and Forecast, 2020 - 2026

Published: | KBV Research | 97 Pages | Delivery time: 1-2 business days

Price

Back to Top
LAMEA Autoinjectors Market By Type, By Application, By End Use, By Country, Industry Analysis and Forecast, 2020 - 2026
Published: December 31, 2020
KBV Research
Content info: 97 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

The Latin America, Middle East and Africa Autoinjectors Market would witness market growth of 18.7% CAGR during the forecast period (2020-2026).

Epinephrine is considered the first line of treatment for allergic reactions or anaphylaxis. Pharmaceutical companies are bringing technologically advanced epinephrine autoinjectors (EAIs) treatment of anaphylaxis. With the advancement in technology including portable devices, innovative designs, autoinjectors with two auto-injectable doses in one device, autoinjectors made with a 0.5- or 0.75-mg dose of epinephrine for larger adults, the autoinjectors are experiencing higher rate of adoptability.

Also, autoinjectors made with a 0.1-mg dose of epinephrine for infants, autoinjectors with enhanced temperature stability and extended shelf life for epinephrine, weather-resistant casing, and devices that can update patients that the dosage was successfully delivered makes the device more user friendly. Factors that are being focused on for improvement of autoinjectors are removal force of safety cap, override force, ejection time, ejection dosage, needle activation force, needle length, dose setting & audible click detection. These technological advancements are anticipated to drive the adoption of autoinjectors significantly in the coming years.

The existing COVID-19 pandemic has brought about the implementation of a new set of protocols that target to decrease patient visits to hospitals and clinics if it is not emergency conditions in order to prevent the spread of the virus. In such a situation, the inclination for home-use autoinjectors has increased among patients who are suffering from allergies and chronic illnesses. This also safeguards susceptible high-risk populations from exposure to the virus while visiting to hospital.

Autoinjectors are being advanced to support improved concentrations and viscosity of drugs to lessen administration frequency, therefore growing adherence to acclaimed drug protocols. These factors facilitate an opportunity for the growth of the market of autoinjectors in the present COVID-19 scenario.

Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Disposable autoinjectors
  • Reusable autoinjectors

By Application

  • Anaphylaxis
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Other Applications

By End Use

  • Hospitals & Clinics
  • Home care settings

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
  • Sanofi S.A.
  • Becton, Dickinson and Company
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • Ypsomed AG
  • AbbVie, Inc.
  • Biogen, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA Autoinjectors Market, by Type
    • 1.4.2 LAMEA Autoinjectors Market, by Application
    • 1.4.3 LAMEA Autoinjectors Market, by End Use
    • 1.4.4 LAMEA Autoinjectors Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Geographical Expansions
    • 3.2.4 Approvals
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
    • 3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, May - 2020, Nov) Leading Players

Chapter 4. LAMEA Autoinjectors Market by Type

  • 4.1 LAMEA Disposable autoinjectors Market by Country
  • 4.2 LAMEA Reusable autoinjectors Market by Country

Chapter 5. LAMEA Autoinjectors Market by Application

  • 5.1 LAMEA Anaphylaxis Market by Country
  • 5.2 LAMEA Rheumatoid Arthritis Market by Country
  • 5.3 LAMEA Multiple Sclerosis Market by Country
  • 5.4 LAMEA Other Application Market by Country

Chapter 6. LAMEA Autoinjectors Market by End Use

  • 6.1 LAMEA Hospitals & Clinics Autoinjectors Market by Country
  • 6.2 LAMEA Home care settings Autoinjectors Market by Country

Chapter 7. LAMEA Autoinjectors Market by Country

  • 7.1 Brazil Autoinjectors Market
    • 7.1.1 Brazil Autoinjectors Market by Type
    • 7.1.2 Brazil Autoinjectors Market by Application
    • 7.1.3 Brazil Autoinjectors Market by End Use
  • 7.2 Argentina Autoinjectors Market
    • 7.2.1 Argentina Autoinjectors Market by Type
    • 7.2.2 Argentina Autoinjectors Market by Application
    • 7.2.3 Argentina Autoinjectors Market by End Use
  • 7.3 UAE Autoinjectors Market
    • 7.3.1 UAE Autoinjectors Market by Type
    • 7.3.2 UAE Autoinjectors Market by Application
    • 7.3.3 UAE Autoinjectors Market by End Use
  • 7.4 Saudi Arabia Autoinjectors Market
    • 7.4.1 Saudi Arabia Autoinjectors Market by Type
    • 7.4.2 Saudi Arabia Autoinjectors Market by Application
    • 7.4.3 Saudi Arabia Autoinjectors Market by End Use
  • 7.5 South Africa Autoinjectors Market
    • 7.5.1 South Africa Autoinjectors Market by Type
    • 7.5.2 South Africa Autoinjectors Market by Application
    • 7.5.3 South Africa Autoinjectors Market by End Use
  • 7.6 Nigeria Autoinjectors Market
    • 7.6.1 Nigeria Autoinjectors Market by Type
    • 7.6.2 Nigeria Autoinjectors Market by Application
    • 7.6.3 Nigeria Autoinjectors Market by End Use
  • 7.7 Rest of LAMEA Autoinjectors Market
    • 7.7.1 Rest of LAMEA Autoinjectors Market by Type
    • 7.7.2 Rest of LAMEA Autoinjectors Market by Application
    • 7.7.3 Rest of LAMEA Autoinjectors Market by End Use

Chapter 8. Company Profiles

  • 8.1 Eli Lilly and Company
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Regional Analysis
    • 8.1.4 Research & Development Expense
    • 8.1.5 Recent strategies and developments:
      • 8.1.5.1 Partnerships, Collaborations, and Agreements:
      • 8.1.5.2 Geographical Expansions:
  • 8.2 GlaxoSmithKline PLC (GSK)
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Segmental and Regional Analysis
    • 8.2.4 Research & Development Expense
    • 8.2.1 Recent strategies and developments:
      • 8.2.1.1 Approvals:
  • 8.3 Merck Group
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental and Regional Analysis
    • 8.3.4 Research & Development Expense
  • 8.4 Sanofi S.A.
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Segmental and Regional Analysis
    • 8.4.4 Research & Development Expense
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Partnerships, Collaborations, and Agreements:
      • 8.4.5.2 Approvals:
      • 8.4.5.3 Product Launches and Product Expansions:
  • 8.5 Becton, Dickinson and Company
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Segmental and Regional Analysis
    • 8.5.4 Research & Development Expense
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Partnerships, Collaborations, and Agreements:
      • 8.5.5.2 Product Launches and Product Expansions:
  • 8.6 Teva Pharmaceutical Industries Ltd.
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Regional Analysis
    • 8.6.4 Research & Development Expenses
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Partnerships, Collaborations, and Agreements:
      • 8.6.5.2 Product Launches and Product Expansions:
      • 8.6.5.3 Approvals:
  • 8.7 Amgen, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Research & Development Expense
    • 8.7.4 Recent strategies and developments:
      • 8.7.4.1 Product Launches and Product Expansions:
  • 8.8 Ypsomed AG
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Segmental and Regional Analysis
    • 8.8.4 Research & Development Expense
  • 8.9 AbbVie, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Regional Analysis
    • 8.9.4 Research & Development Expenses
    • 8.9.5 Recent strategies and developments:
      • 8.9.5.1 Partnerships, Collaborations, and Agreements:
  • 8.10. Biogen, Inc.
    • 8.10.1 Company Overview
    • 8.10.2 Financial Analysis
    • 8.10.3 Regional Analysis
    • 8.10.4 Research & Development Expenses
    • 8.10.5 Recent strategies and developments:
      • 8.10.5.1 Partnerships, Collaborations, and Agreements:

LIST OF TABLES

  • TABLE 1 LAMEA AUTOINJECTORS MARKET, 2016 - 2019, USD MILLION
  • TABLE 2 LAMEA AUTOINJECTORS MARKET, 2020 - 2026, USD MILLION
  • TABLE 3 PARTNERSHIPS, COLLABORATIONS AND AGREEMENTS- AUTO-INJECTORS MARKET
  • TABLE 4 PRODUCT LAUNCHES AND PRODUCT EXPANSIONS- AUTO-INJECTORS MARKET
  • TABLE 5 GEOGRAPHICAL EXPANSIONS- AUTO-INJECTORS MARKET
  • TABLE 6 APPROVALS- AUTO-INJECTORS MARKET
  • TABLE 7 LAMEA AUTOINJECTORS MARKET BY TYPE, 2016 - 2019, USD MILLION
  • TABLE 8 LAMEA AUTOINJECTORS MARKET BY TYPE, 2020 - 2026, USD MILLION
  • TABLE 9 LAMEA DISPOSABLE AUTOINJECTORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 10 LAMEA DISPOSABLE AUTOINJECTORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 11 LAMEA REUSABLE AUTOINJECTORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 12 LAMEA REUSABLE AUTOINJECTORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 13 LAMEA AUTOINJECTORS MARKET BY APPLICATION, 2016 - 2019, USD MILLION
  • TABLE 14 LAMEA AUTOINJECTORS MARKET BY APPLICATION, 2020 - 2026, USD MILLION
  • TABLE 15 LAMEA ANAPHYLAXIS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 16 LAMEA ANAPHYLAXIS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 17 LAMEA RHEUMATOID ARTHRITIS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 18 LAMEA RHEUMATOID ARTHRITIS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 19 LAMEA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 20 LAMEA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 21 LAMEA OTHER APPLICATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 22 LAMEA OTHER APPLICATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 23 LAMEA AUTOINJECTORS MARKET BY END USE, 2016 - 2019, USD MILLION
  • TABLE 24 LAMEA AUTOINJECTORS MARKET BY END USE, 2020 - 2026, USD MILLION
  • TABLE 25 LAMEA HOSPITALS & CLINICS AUTOINJECTORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 26 LAMEA HOSPITALS & CLINICS AUTOINJECTORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 27 LAMEA HOME CARE SETTINGS AUTOINJECTORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 28 LAMEA HOME CARE SETTINGS AUTOINJECTORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 29 LAMEA AUTOINJECTORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 30 LAMEA AUTOINJECTORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 31 BRAZIL AUTOINJECTORS MARKET, 2016 - 2019, USD MILLION
  • TABLE 32 BRAZIL AUTOINJECTORS MARKET, 2020 - 2026, USD MILLION
  • TABLE 33 BRAZIL AUTOINJECTORS MARKET BY TYPE, 2016 - 2019, USD MILLION
  • TABLE 34 BRAZIL AUTOINJECTORS MARKET BY TYPE, 2020 - 2026, USD MILLION
  • TABLE 35 BRAZIL AUTOINJECTORS MARKET BY APPLICATION, 2016 - 2019, USD MILLION
  • TABLE 36 BRAZIL AUTOINJECTORS MARKET BY APPLICATION, 2020 - 2026, USD MILLION
  • TABLE 37 BRAZIL AUTOINJECTORS MARKET BY END USE, 2016 - 2019, USD MILLION
  • TABLE 38 BRAZIL AUTOINJECTORS MARKET BY END USE, 2020 - 2026, USD MILLION
  • TABLE 39 ARGENTINA AUTOINJECTORS MARKET, 2016 - 2019, USD MILLION
  • TABLE 40 ARGENTINA AUTOINJECTORS MARKET, 2020 - 2026, USD MILLION
  • TABLE 41 ARGENTINA AUTOINJECTORS MARKET BY TYPE, 2016 - 2019, USD MILLION
  • TABLE 42 ARGENTINA AUTOINJECTORS MARKET BY TYPE, 2020 - 2026, USD MILLION
  • TABLE 43 ARGENTINA AUTOINJECTORS MARKET BY APPLICATION, 2016 - 2019, USD MILLION
  • TABLE 44 ARGENTINA AUTOINJECTORS MARKET BY APPLICATION, 2020 - 2026, USD MILLION
  • TABLE 45 ARGENTINA AUTOINJECTORS MARKET BY END USE, 2016 - 2019, USD MILLION
  • TABLE 46 ARGENTINA AUTOINJECTORS MARKET BY END USE, 2020 - 2026, USD MILLION
  • TABLE 47 UAE AUTOINJECTORS MARKET, 2016 - 2019, USD MILLION
  • TABLE 48 UAE AUTOINJECTORS MARKET, 2020 - 2026, USD MILLION
  • TABLE 49 UAE AUTOINJECTORS MARKET BY TYPE, 2016 - 2019, USD MILLION
  • TABLE 50 UAE AUTOINJECTORS MARKET BY TYPE, 2020 - 2026, USD MILLION
  • TABLE 51 UAE AUTOINJECTORS MARKET BY APPLICATION, 2016 - 2019, USD MILLION
  • TABLE 52 UAE AUTOINJECTORS MARKET BY APPLICATION, 2020 - 2026, USD MILLION
  • TABLE 53 UAE AUTOINJECTORS MARKET BY END USE, 2016 - 2019, USD MILLION
  • TABLE 54 UAE AUTOINJECTORS MARKET BY END USE, 2020 - 2026, USD MILLION
  • TABLE 55 SAUDI ARABIA AUTOINJECTORS MARKET, 2016 - 2019, USD MILLION
  • TABLE 56 SAUDI ARABIA AUTOINJECTORS MARKET, 2020 - 2026, USD MILLION
  • TABLE 57 SAUDI ARABIA AUTOINJECTORS MARKET BY TYPE, 2016 - 2019, USD MILLION
  • TABLE 58 SAUDI ARABIA AUTOINJECTORS MARKET BY TYPE, 2020 - 2026, USD MILLION
  • TABLE 59 SAUDI ARABIA AUTOINJECTORS MARKET BY APPLICATION, 2016 - 2019, USD MILLION
  • TABLE 60 SAUDI ARABIA AUTOINJECTORS MARKET BY APPLICATION, 2020 - 2026, USD MILLION
  • TABLE 61 SAUDI ARABIA AUTOINJECTORS MARKET BY END USE, 2016 - 2019, USD MILLION
  • TABLE 62 SAUDI ARABIA AUTOINJECTORS MARKET BY END USE, 2020 - 2026, USD MILLION
  • TABLE 63 SOUTH AFRICA AUTOINJECTORS MARKET, 2016 - 2019, USD MILLION
  • TABLE 64 SOUTH AFRICA AUTOINJECTORS MARKET, 2020 - 2026, USD MILLION
  • TABLE 65 SOUTH AFRICA AUTOINJECTORS MARKET BY TYPE, 2016 - 2019, USD MILLION
  • TABLE 66 SOUTH AFRICA AUTOINJECTORS MARKET BY TYPE, 2020 - 2026, USD MILLION
  • TABLE 67 SOUTH AFRICA AUTOINJECTORS MARKET BY APPLICATION, 2016 - 2019, USD MILLION
  • TABLE 68 SOUTH AFRICA AUTOINJECTORS MARKET BY APPLICATION, 2020 - 2026, USD MILLION
  • TABLE 69 SOUTH AFRICA AUTOINJECTORS MARKET BY END USE, 2016 - 2019, USD MILLION
  • TABLE 70 SOUTH AFRICA AUTOINJECTORS MARKET BY END USE, 2020 - 2026, USD MILLION
  • TABLE 71 NIGERIA AUTOINJECTORS MARKET, 2016 - 2019, USD MILLION
  • TABLE 72 NIGERIA AUTOINJECTORS MARKET, 2020 - 2026, USD MILLION
  • TABLE 73 NIGERIA AUTOINJECTORS MARKET BY TYPE, 2016 - 2019, USD MILLION
  • TABLE 74 NIGERIA AUTOINJECTORS MARKET BY TYPE, 2020 - 2026, USD MILLION
  • TABLE 75 NIGERIA AUTOINJECTORS MARKET BY APPLICATION, 2016 - 2019, USD MILLION
  • TABLE 76 NIGERIA AUTOINJECTORS MARKET BY APPLICATION, 2020 - 2026, USD MILLION
  • TABLE 77 NIGERIA AUTOINJECTORS MARKET BY END USE, 2016 - 2019, USD MILLION
  • TABLE 78 NIGERIA AUTOINJECTORS MARKET BY END USE, 2020 - 2026, USD MILLION
  • TABLE 79 REST OF LAMEA AUTOINJECTORS MARKET, 2016 - 2019, USD MILLION
  • TABLE 80 REST OF LAMEA AUTOINJECTORS MARKET, 2020 - 2026, USD MILLION
  • TABLE 81 REST OF LAMEA AUTOINJECTORS MARKET BY TYPE, 2016 - 2019, USD MILLION
  • TABLE 82 REST OF LAMEA AUTOINJECTORS MARKET BY TYPE, 2020 - 2026, USD MILLION
  • TABLE 83 REST OF LAMEA AUTOINJECTORS MARKET BY APPLICATION, 2016 - 2019, USD MILLION
  • TABLE 84 REST OF LAMEA AUTOINJECTORS MARKET BY APPLICATION, 2020 - 2026, USD MILLION
  • TABLE 85 REST OF LAMEA AUTOINJECTORS MARKET BY END USE, 2016 - 2019, USD MILLION
  • TABLE 86 REST OF LAMEA AUTOINJECTORS MARKET BY END USE, 2020 - 2026, USD MILLION
  • TABLE 87 KEY INFORMATION - ELI LILLY AND COMPANY
  • TABLE 88 KEY INFORMATION - GLAXOSMITHKLINE PLC (GSK)
  • TABLE 89 KEY INFORMATION - MERCK GROUP
  • TABLE 90 KEY INFORMATION - SANOFI S.A.
  • TABLE 91 KEY INFORMATION - BECTON, DICKINSON AND COMPANY
  • TABLE 92 KEY INFORMATION - TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • TABLE 93 KEY INFORMATION - AMGEN, INC.
  • TABLE 94 KEY INFORMATION --YPSOMED AG
  • TABLE 95 KEY INFORMATION - ABBVIE, INC.
  • TABLE 96 KEY INFORMATION - BIOGEN, INC.

LIST OF FIGURES

  • FIG 1 METHODOLOGY FOR THE RESEARCH
  • FIG 2 KBV CARDINAL MATRIX
  • FIG 3 KEY LEADING STRATEGIES: PERCENTAGE DISTRIBUTION (2016-2020)
  • FIG 4 KEY STRATEGIC MOVE: (PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS : 2016, MAY - 2020, NOV) LEADING PLAYERS
  • FIG 5 RECENT STRATEGIES AND DEVELOPMENTS: ELI LILLY AND COMPANY
  • FIG 6 RECENT STRATEGIES AND DEVELOPMENTS: SANOFI S.A.
  • FIG 7 RECENT STRATEGIES AND DEVELOPMENTS: BECTON, DICKINSON AND COMPANY
  • FIG 8 RECENT STRATEGIES AND DEVELOPMENTS: TEVA PHARMACEUTICALS INDUSTRIES LTD.